Probiotic foods and drugs: impact of US regulatory status on design of clinical trials.
Probiotic foods and drugs: impact of US regulatory status on design of clinical trials.
复制标题
益生菌食品和药物：美国监管状况对临床试验设计的影响。
DOI：
10.1086/523321
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
Davidson,Lisa
中科院分区：
文献类型：
--
作者：
Hibberd,PatriciaL;Davidson,Lisa
Probiotics have been in widespread use since ancient times and are increasingly being consumed to maintain health and to prevent and treat a wide range of conditions. In the United States, probiotics are considered to be foods or biologics, depending on their intended use. This article addresses the similarities and differences between approaches to conducting clinical trials of probiotics as foods (which leads to health claims) or as biologics (which leads to therapeutic claims). Most probiotics are manufactured as foods, which makes it challenging for academic investigators in the United States to meet the requirements of an Investigational New Drug application that enables them to study the therapeutic effects of these novel agents. Although it is important to ensure the safety and quality of probiotic products, there also may be value in adapting the US Food and Drug Administration'sGuidance for Industry for Botanical Productsto probiotic products, in part to allow the research agenda to move forward with products for which there are no safety concerns.
登录
查看更多内容
影响因子：
4.2
作者：
Näse, L;Hatakka, K;Meurman, JH
通讯作者：
Meurman, JH
影响因子：
4.7
作者：
Chiang, BL;Sheih, YH;Gill, HS
通讯作者：
Gill, HS
影响因子：
64.5
作者：
Rakoff-Nahoum, S;Paglino, J;Medzhitov, R
通讯作者：
Medzhitov, R
影响因子：
168.9
作者：
Kalliomäki, M;Salminen, S;Isolauri, E
通讯作者：
Isolauri, E
三天抗菌治疗和乳酸菌阴道栓剂对尿路感染复发的影响。
影响因子：
3.2
作者：
G. Reid;A. Bruce;M. Taylor
通讯作者：
M. Taylor